The timeline of nanobody development reflects a steady series of innovations. In 2001, the term "nanobody" was introduced by ...

AL101, a human monoclonal antibody, is being jointly developed by ... progression using the Clinical Dementia Rating Sum of Boxes (CDR-SB), an instrument that tracks cognitive impairments in ...

Ingelheim, Germany, May 6, 2025 - Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential ...

Alzheimer's drug shows long-term benefits in behavior and cognition. EU approval of Blarcamesine could boost its market value ...

New data show that lecanemab is well tolerated outside of clinical trial setting, with expected and manageable side effects.

Opella on May 8 announced that it is now a standalone company after Sanofi completed the closing of the sale of 50 per cent ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately ...